spacer
home > ebr > autumn 2017 > unleashing 3d
PUBLICATIONS
European Biopharmaceutical Review

Unleashing 3D

The last 10 years have seen a dramatic surge in the number of publications about organoids – but what are they and why is everyone talking about them? In simple terms, they are miniature organs grown in vitro in a near-physiological 3D environment. Unlike simple tissue cultures, they retain features of the organ they are derived from, including important structural and functional properties, and many believe that they could dramatically accelerate the understanding of human biology and disease progression.

Traditional 2D cell culture has brought great progress in understanding human development over the last 50 years. However, studying organogenesis in vitro has been hindered by the lack of appropriate systems that would allow the cell-to-cell interactions needed for organ formation. Organoids provide the accurate and physiologically relevant models that are needed to overcome this deficiency.

So-called organoids have now been derived from gut, kidney, pancreas, liver and brain tissue, and growing these mini-organs has been made possible by the recent advances in stem cell systems and the development of 3D support matrices. Thanks to this new technology, cells derived from stem cells or organ progenitors can self-organise through cell sorting and recapitulate the complexity of mammalian organogenesis in vitro in a way that is similar to how they do in vivo.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Colin Sanctuary is a biomedical engineer and Chief Executive Officer at QGel. Following his PhD in biomedical engineering at École Polytechnique Fédérale de Lausanne, Switzerland, Colin worked in product development and later in global marketing in the medical device and pharma industries. In 2009, he co-founded QGel with the aim of building a company that contributes to improving R&D productivity in pharma, particularly in the area of developing novel anticancer treatments.
spacer
Dr Colin Sanctuary
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Pharma Services Completes Acquisition of Sherpa Clinical Packaging

Philadelphia, USA – October 2, 2018 Leading global biopharmaceutical outsourcing services provider PCI Pharma Services (PCI) has announced the completion of its acquisition of Sherpa Clinical Packaging (Sherpa).
More info >>

White Papers

Advantages of Quantitative NMR for the Determination of Relative Response Factors

Novatia, LLC

Quantitative NMR (qNMR) is a technique that is being applied broadly and at an increasing rate in the field of pharmaceutical analysis (1). This white paper highlights the advantages of using qNMR to determine Relative Response Factors (RRFs) for pharmaceutical impurities detectable by HPLC. A single determination of RRFs using qNMR allows for simple and accurate quantitation of impurities which eliminates the need for preparation, qualification, and storage of reference standards. An example is presented here, which demonstrates quantitation of known impurities that have variable responses to UV-VIS detection, thereby providing a more accurate assessment of impurity levels than UV-VIS response alone.
More info >>

 
Industry Events

Pharma Packaging and Labelling East Coast 2019

20-21 February 2019, Phildaelphia, USA

Now in its 11th year, Pharma Packaging and Labeling is back to deliver key, actionable insights into very latest regulatory requirements, technological innovations, strategic developments, and how to implement them into your packaging and labeling chain with both maximum efficiency and minimal cost.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement